United Therapeutics Stock Earnings Reports

United Therapeutics reported strong Q1 2026 results with $782 million in revenue despite some seasonality, winter weather and pharmacy operational disruptions that affected February. Management highlighted two recent Phase III successes: ralinepag (ADVANCE OUTCOMES) in PAH and nebulized Tyvaso (TETON 1 & 2) in IPF, each described as best-in-class with the potential to materially expand addressable markets. The company expects to file a supplemental NDA for nebulized Tyvaso in IPF by the end of this summer with possible priority review and a launch as early as Q2 next year on a standard review timeline. Ralinepag is positioned as a once-daily oral “super prostacyclin” with industry-leading outcomes and management expects a mid-next-year launch for oral ralinepag assuming a smooth FDA review. United is also advancing an inhaled DPI formulation of ralinepag (RALDPI) developed with MannKind; the company plans a Phase I (healthy volunteer) study with completion expected before year-end and anticipates rapid progression into efficacy studies for PAH, PH-ILD, IPF and PPF. Commercial strategy emphasizes multiple delivery formats (nebulized, DPI, SMI, oral) to maximize patient uptake and persistence, leveraging existing commercial infrastructure and planned salesforce expansion. Management projects this pipeline could drive revenue well beyond the current ~$3 billion run rate, targeting a $3–4 billion run rate by end of 2027 and expecting the new products to more than double revenues in the following years. Key near-term milestones: sNDA filing for Tyvaso IPF (by end of summer), Phase I IND/PK for RALDPI (data by year-end), and anticipated FDA review/launch timelines for ralinepag and Tyvaso IPF next year.